martes, 22 de junio de 2010

Immunosuppression after kidney transplantation. In: Guidelines on renal transplantation.


GUIDELINE TITLE
Immunosuppression after kidney transplantation. In: Guidelines on renal transplantation.

BIBLIOGRAPHIC SOURCE(S)
Immunosuppression after kidney transplantation. In: Kälble T, Alcaraz A, Budde K, Humke U, Karam G, Lucan M, Nicita G, Süsal C. Guidelines on renal transplantation. Arnhem, The Netherlands: European Association of Urology (EAU); 2009 Mar. p. 55-65. [78 references]


GUIDELINE STATUS
This is the current release of the guideline.

** REGULATORY ALERT **
FDA WARNING/REGULATORY ALERT

Note from the National Guideline Clearinghouse: This guideline references a drug(s) for which important revised regulatory and/or warning information has been released.

August 14, 2009 – CellCept (mycophenolate mofetil), September 04, 2009 – Myfortic (mycophenolic acid): The U.S. Food and Drug Administration (FDA) and Roche notified healthcare professionals that cases of Pure Red Cell Aplasia (PRCA) have been reported in patients treated with CellCept. Additionally, the USDA and Novartis notified healthcare professionals that cases of PRCA have been reported in patients treated with Myfortic. The WARNINGS and ADVERSE REACTIONS sections of the Prescribing Information for both drugs have been revised to reflect this new safety information.
July 14, 2009 – Sirolimus (Rapamune), Cyclosporine (Sandimmune or Neoral and generics), Mycophenolate mofetil (Cellcept and generics), Mycophenolic acid (Myfortic): The U.S. Food and Drug Administration (FDA) is requiring the makers of certain immunosuppressant drugs to update their labeling to reflect that immunosuppressed patients are at increased risk for opportunistic infections, such as activation of latent viral infections, including BK virus-associated nephropathy.

open here to see the full-text:
Immunosuppression after kidney transplantation. In: Guidelines on renal transplantation.

No hay comentarios:

Publicar un comentario